EMA Highlights: Green light for rare cancer treatments
by Gary Finnegan: Survival rates in young patients with high-risk neuroblastoma can be improved by Unituxin (dinutuximab), a new treatment approved by the European Medicines Agency (EMA).
by Gary Finnegan: Survival rates in young patients with high-risk neuroblastoma can be improved by Unituxin (dinutuximab), a new treatment approved by the European Medicines Agency (EMA).
by Bruce Sylvester: Weakening grip strength is associated with increasing overall mortality and with increasing risk of heart attack or stroke, researchers from a large international study reported… read more.
by Bruce Sylvester: Older adults who use cholesterol-lowering statins or fibrates have one third less risk of stroke than their untreated counterparts, researchers reported on May 19, 2015… read more.
by Bruce Sylvester: Investigators from the phase III PALOMA-3 trial report that treatment with the recently FDA-approved drug palbociclib more than doubled the time to cancer recurrence among… read more.
by Bruce Sylvester: Treatment of advanced melanoma with a combination of nivolumab (Opdivo™) and ipilimumab (Yervoy™) or with nivolumab alone increases progression-free survival over ipilimumab monotherapy, researchers reported… read more.
by Bruce Sylvester: Anastrozole is significantly more effective than tamoxifen in preventing cancer recurrence after lumpectomy and radiation therapy in postmenopausal women, age 60 or younger with DCIS… read more.
by Bruce Sylvester: Pembrolizumab (Keytruda®), an anti-PD-1 antibody immunotherapy has shown efficacy in one fourth of patients with recurrent or metastatic head and neck cancer, researchers reported on… read more.
by Bruce Sylvester: In a Phase III trial comparing standard docetaxel chemotherapy with immunotherapy nivolumab, researchers reported that subjects with squamous-non-small cell lung cancer treated with nivolumab lived… read more.
by Christine Clark: The National Cancer Information Network (NCIN) was established to drive change and improve cancer outcomes. Analyses show large variations in practices and outcomes some of… read more.
Dr Graham Collins from the Oxford Cancer and Haematology Centre, Oxford, UK.
Graham Jackson, Professor of Clinical haematology, Newcastle upon Tyne and former president of the British Society for Haematology (BSH). Article by Christine Clark: In the 1970s the prospect… read more.
Professor Graham Jackson, Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.